NKGen Biotech Files 8-K on Equity Sales
| Field | Detail |
|---|---|
| Company | Nkgen Biotech, Inc. |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, definitive-agreement, company-name-change
Related Tickers: NKGN
TL;DR
NKGen Biotech filed an 8-K for unregistered equity sales on May 5, 2025.
AI Summary
On May 5, 2025, NKGen Biotech, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, formerly known as Graf Acquisition Corp. IV, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates potential new equity financing or sales, which could impact the company's capital structure and stock dilution.
Risk Assessment
Risk Level: medium — Unregistered equity sales can sometimes signal financial distress or dilutionary financing, requiring further investigation.
Key Players & Entities
- NKGen Biotech, Inc. (company) — Registrant
- Graf Acquisition Corp. IV (company) — Former Company Name
- May 5, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific type of equity securities were sold?
The filing mentions 'Unregistered Sales of Equity Securities' but does not specify the exact type of securities in the provided text.
Were these sales to accredited investors or a limited number of purchasers?
The filing indicates 'Unregistered Sales of Equity Securities,' which typically implies sales made under an exemption from registration, often to accredited investors or a limited group.
What is the purpose of these unregistered equity sales?
The provided text does not explicitly state the purpose of the unregistered equity sales.
When was NKGen Biotech, Inc. formerly known as Graf Acquisition Corp. IV?
The date of the name change from Graf Acquisition Corp. IV to NKGen Biotech, Inc. was February 10, 2021.
What is the SIC code for NKGen Biotech, Inc.?
The Standard Industrial Classification (SIC) code for NKGen Biotech, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding NKGen Biotech, Inc..